nach oben

DGNeurologie

Erschienen in:

26.07.2021 | Sialadenitis | CME Zertifizierte Fortbildung

Neuro-Sjögren

verfasst von: Dr. T. Seeliger, Dr. N. K. Prenzler, Prof. Dr. T. Witte, Prof. Dr. T. Skripuletz

Erschienen in: DGNeurologie | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Sjögren-Syndrom ist eine autoimmune Erkrankung, die sich in einer Sicca-Symptomatik in Auge und Mund, aber auch extraglandulär im zentralen und peripheren Nervensystem manifestieren kann. Die neurologische Beteiligung äußert sich dabei meist in Form einer Polyneuropathie, aber auch Hirnnervenausfälle, Myopathien, Myelitiden, Zerebellitiden und Enzephalitiden können auftreten. Die Schwere der Krankheitsverläufe wurde hierbei lange unterschätzt. Das Sjögren-Syndrom betrifft vorrangig Frauen, aber bei Vorliegen eines Neuro-Sjögrens wird ein ausgewogenes Geschlechterverhältnis beobachtet. Die Diagnose wird über das Vorliegen einer objektiven Sicca-Symptomatik, den Nachweis von SSA(Ro)-Antikörpern (SSA: „Sjögren’s-syndrome-related antigen“) und/oder einer Sialadenitis in der Unterlippenspeicheldrüsenbiopsie gestellt. Die Patienten mit extraglandulären Manifestationen profitieren von einer immunmodulierenden Therapie.

Seror R, Ravaud P, Bowman SJ et al (2010) EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 69:1103–1109PubMed

Sogkas G, Hirsch S, Olsson KM et al (2020) Lung involvement in primary Sjögren’s syndrome—an under-diagnosed entity. Front Med 7:332. https://doi.org/10.3389/fmed.2020.00332CrossRef

Theander E, Henriksson G, Ljungberg O et al (2006) Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 65:796–803PubMed

Sivadasan A, Muthusamy K, Patel B et al (2017) Clinical spectrum, therapeutic outcomes, and prognostic predictors in Sjogren’s syndrome-associated neuropathy. Ann Indian Acad Neurol 20:278–283PubMedPubMedCentral

Seeliger T, Jacobsen L, Hendel M et al (2020) Cognitive impairment in patients with Neuro-Sjögren. Ann Clin Transl Neurol 7:1352–1359PubMedPubMedCentral

Delalande S, de Seze J, Fauchais A-L et al (2004) Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine 83:280–291PubMed

Mori K, Iijima M, Koike H et al (2005) The wide spectrum of clinical manifestations in Sjögren’s syndrome-associated neuropathy. Brain 128:2518–2534PubMed

Teixeira F, Moreira I, Silva AM et al (2013) Neurological involvement in primary Sjögren syndrome. Acta Reumatol Port 38:29–36PubMed

Altorok N, Coit P, Hughes T et al (2014) Genome-wide DNA methylation patterns in naive cd4+ t cells from patients with primary sjögren’s syndrome. Arthritis Rheumatol 66:731–739PubMedPubMedCentral

10.

Porola P, Virkki L, Przybyla BD et al (2008) Androgen deficiency and defective intracrine processing of dehydroepiandrosterone in salivary glands in Sjögren’s syndrome. J Rheumatol 35:2229–2235PubMed

11.

Wang J, Syrett CM, Kramer MC et al (2016) Unusual maintenance of X chromosome inactivation predisposes female lymphocytes for increased expression from the inactive X. Proc Natl Acad Sci U S A 113:E2029–E2038PubMedPubMedCentral

12.

Triantafyllopoulou A, Moutsopoulos H (2007) Persistent viral infection in primary Sjogren’s syndrome: review and perspectives. Clin Rev Allergy Immunol 32:210–214PubMed

13.

Ramos-Casals M, Solans R, Rosas J et al (2008) Primary Sjögren syndrome in Spain. Medicine 87:210–219PubMed

14.

Chai J, Logigian EL (2010) Neurological manifestations of primary Sjogren’s syndrome. Curr Opin Neurol 23:509–513PubMed

15.

Griffin JW, Cornblath DR, Alexander E et al (1990) Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren’s syndrome. Ann Neurol 27:304–315PubMed

16.

Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American college of rheumatology/European league against rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 69:35–45PubMed

17.

Brito-Zerón P, Akasbi M, Bosch X et al (2013) Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjögren’s syndrome. Clin Exp Rheumatol 31:103–110PubMed

18.

Chisholm DM, Mason DK (1968) Labial salivary gland biopsy in Sjogren’s disease

19.

de Seze J, Dubucquoi S, Fauchais AL et al (2003) α-Fodrin autoantibodies in the differential diagnosis of MS and Sjögren syndrome. Neurology 61:268–269PubMed

20.

21.

Stefanski AL, Tomiak C, Pleyer U et al (2017) The diagnosis and treatment of Sjögren’s syndrome. Dtsch Arztebl Int 114(20):354–361. https://doi.org/10.3238/arztebl.2017.0354CrossRefPubMedPubMedCentral

22.

Jaskólska M, Chylińska M, Masiak A et al (2020) Neuro-Sjögren: uncommon or underestimated problem? Brain Behav 10(8):e1665. https://doi.org/10.1002/brb3.1665CrossRefPubMedPubMedCentral

23.

Seeliger T, Prenzler NK, Gingele S et al (2019) Neuro-Sjögren: peripheral neuropathy with limb weakness in Sjögren’s syndrome. Front Immunol 10:1600PubMedPubMedCentral

24.

Lin Y-K, Yang F-C, Liu F-C et al (2016) Co-occurrence of Guillain-Barre syndrome and primary Sjogren syndrome in an elderly woman. Acta Neurol Taiwan 25:83–87PubMed

25.

Garza-Alpirez A, Arana-Guajardo AC, Esquivel-Valerio JA et al (2017) Hypokalemic paralysis due to primary Sjögren syndrome: case report and review of the literature. Case Rep Rheumatol 2017:7509238PubMedPubMedCentral

26.

Thiele T, Seeliger T, Witte T et al (2020) Severe polyneuropathy in primary Sjögren’s syndrome: Sjögren’s syndrome should be considered in patients with motor neuropathy. Z Rheumatol 79:707–709PubMed

27.

Seeliger T, Gingele S, Bönig L et al (2021) CIDP associated with Sjögren’s syndrome. J Neurol. https://doi.org/10.1007/s00415-021-10459-zCrossRefPubMed

28.

Van den Bergh PYK, Hadden RDM, Bouche P et al (2010) European federation of neurological societies/peripheral nerve society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European federation of neurological societies and the peripheral nerve society—first revision. Eur J Neurol. https://doi.org/10.1111/j.1468-1331.2009.02930.xCrossRefPubMed

29.

Pars K, Pul R, Schwenkenbecher P et al (2017) Cerebrospinal fluid findings in neurological diseases associated with Sjögren’s syndrome. Eur Neurol 77:91–102PubMed

30.

Butryn M, Neumann J, Rolfes L et al (2020) Clinical, radiological, and laboratory features of spinal cord involvement in primary Sjögren’s syndrome. J Clin Med 9:1482PubMedCentral

31.

Vrethem M, Ernerudh J, Lindström F, Skogh T (1990) Immunoglobulins within the central nervous system in primary Sjögren’s syndrome. J Neurol Sci 100:186–192PubMed

32.

Harboe E, Tjensvoll AB, Maroni S et al (2009) Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjögren syndrome: a comparative population-based study. Ann Rheum Dis 68:1541–1546PubMed

33.

Westhoff G, Dorner T, Zink A (2012) Fatigue and depression predict physician visits and work disability in women with primary Sjogren’s syndrome: results from a cohort study. Baillieres Clin Rheumatol 51:262–269

34.

Ramos-Casals M, Brito-Zerón P, Bombardieri S et al (2020) EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann Rheum Dis 79:3–18PubMed

35.

Seror R, Theander E, Brun JG et al (2015) Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 74:859–866PubMed

36.

Gottenberg JE, Ravaud P, Puéchal X et al (2014) Effects of hydroxychloroquine on symptomatic improvement in primary sjögren syndrome: the JOQUER randomized clinical trial. JAMA 312:249–258PubMed

37.

Yoon CH, Lee HJ, Lee EY et al (2016) Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sjögren’s syndrome: a double-blind randomized control study. J Korean Med Sci 31:1127–1135PubMedPubMedCentral

38.

Pereira PR, Viala K, Maisonobe T et al (2016) Sjögren sensory neuronopathy (Sjögren ganglionopathy): long-term outcome and treatment response in a series of 13 cases. Medicine 95:e3632PubMedPubMedCentral

39.

Vivino FB, Carsons SE, Foulks G et al (2016) New treatment guidelines for Sjögren’s disease. Rheum Dis Clin North Am 42:531–551PubMedPubMedCentral

40.

Kastrup O, Maschke M, Diener HC (2005) Pulse—cyclophosphamide in the treatment of ataxic sensory and cranial nerve neuropathy associated with Sjogren’s syndrome. Clin Neurol Neurosurg 107:440–441PubMed

41.

Brito-Zerón P, Acar-Denizli N, Ng W-F et al (2018) How immunological profile drives clinical phenotype of primary Sjögren’s syndrome at diagnosis: analysis of 10,500 patients (Sjögren big data project). Clin Exp Rheumatol 36(112):102–112PubMed

42.

Rist S, Sellam J, Hachulla E et al (2011) Experience of intravenous immunoglobulin therapy in neuropathy associated with primary Sjögren’s syndrome: a national multicentric retrospective study. Arthritis Care Res (Hoboken) 63:1339–1344

43.

Wakasugi D, Kato T, Gono T et al (2009) Extreme efficacy of intravenous immunoglobulin therapy for severe burning pain in a patient with small fiber neuropathy associated with primary Sjögren’s syndrome. Mod Rheumatol 19:437–440PubMed

44.

Morozumi S, Kawagashira Y, Iijima M et al (2009) Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren’s syndrome. J Neurol Sci 279:57–61PubMed

45.

Cornec D, Devauchelle-Pensec V, Tobón GJ et al (2012) B cells in Sjögren’s syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun 39:161–167PubMed

46.

Fisher BA, Everett CC, Rout J et al (2018) Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’s syndrome: results of the TRACTISS randomised double-blind multicentre substudy. Ann Rheum Dis 77:412–416PubMed

47.

Meijer JM, Meiners PM, Vissink A et al (2010) Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:960–968PubMed

48.

Dass S, Bowman SJ, Vital EM et al (2008) Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 67:1541–1544PubMed

49.

Gottenberg JE, Cinquetti G, Larroche C et al (2013) Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: results in 78 patients of the autoimmune and rituximab registry. Ann Rheum Dis 72:1026–1031PubMed

50.

Mekinian A, Ravaud P, Hatron PY et al (2012) Efficacy of rituximab in primary Sjögren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 71:84–87PubMed

51.

Bowman SJ, Everett CC, O’Dwyer JL et al (2017) Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome. Arthritis Rheumatol 69:1440–1450PubMed

52.

Devauchelle-Pensec V, Mariette X, Jousse-Joulin S et al (2014) Treatment of primary Sjögren syndrome with rituximab. Ann Intern Med 160:233–242PubMed

Titel: Neuro-Sjögren
verfasst von: Dr. T. Seeliger
Dr. N. K. Prenzler
Prof. Dr. T. Witte
Prof. Dr. T. Skripuletz
Publikationsdatum: 26.07.2021
Verlag: Springer Medizin
Schlagwörter: Sialadenitis
Krankheiten des peripheren Nervensystems
Polyneuropathie
Sialadenitis
Erschienen in: DGNeurologie / Ausgabe 5/2021
Print ISSN: 2524-3446
Elektronische ISSN: 2524-3454
DOI: https://doi.org/10.1007/s42451-021-00363-1

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Mitteilungen der Deutschen Gesellschaft für Neurologie

Diagnose gesucht – Vernichtungskopfschmerz & Kaliberschwankungen der intrakranialen Gefäße

56-jährige Patientin mit rasch progredientem, atraumatischem Konus-Kauda-Syndrom

Neurologie stärken – sowohl auf ärztlicher als auch pflegerischer Seite

Magazin

Idiopathische intrakraniale Hypertension